

Press Release

Cytochroma Appoints World Leading Researchers To Scientific Advisory Board

MARKHAM, Ontario, Canada – October 1, 2002 - Cytochroma Inc. announced today that the Company has formed a new Scientific Advisory Board (SAB) made up of internationally renowned researchers to accelerate Cytochroma's target validation and drug discovery efforts. New members Drs. Pierre Chambon, John R. Falck, David Feldman and Reuben Lotan join previous SAB members Drs. Michael R. Waterman and Roger Deeley.

Following a successful round of financing, Cytochroma has recruited this group of world-class researchers to focus on enhancing and refining its drug discovery approach. "I am extremely enthusiastic about working with scientists of such high caliber," stated Dr. Bozena Korczak, Vice-President, R&D of Cytochroma. "The new SAB brings together a group of scientists with broad knowledge and expertise to advise Cytochroma on the critical scientific and clinical decisions in its next period of growth."

Members of Cytochroma's Scientific Advisory Board include:

Pierre Chambon, M.D. is the world's foremost expert in the field of gene structure and regulation, nuclear signal transduction and deciphering retinoic acid dependent pathways. He has won numerous international prizes for his pioneering work in these areas. With an estimated seven hundred peer reviewed publications, Dr. Chambon, Professor at the Collège de France, created the Institut de Génétique et de Biologie Moléculaire et Cellulaire (Université Louis Pasteur, CNRS, INSERM) and directs the Génopole Strasbourg Alsace-Lorraine; and the Institut Clinique de la Souris. Dr. Chambon serves on a number of editorial boards, including Cell, Molecular Cell and Genes and Development. Dr. Chambon also serves on various scientific boards, including Council of Scientific Advisors – ICGEB(Trieste), Exonhit, Deltagen and CareX.

Roger G. Deeley, Ph.D. is the Stauffer Research Professor and Director, Cancer Research Laboratories, Queen's University, Kingston, Ontario and Head of Research, Cancer Care Ontario. An expert in gene regulation, novel transcription factors and the co-discoverer of the multidrug resistance protein (MRP), Dr. Deeley publishes extensively on mechanisms of drug resistance and holds several patents in this area. Dr. Deeley also consults for a number of health care companies including ISIS Pharmaceuticals and Eli Lilly Pharmaceutical Company.

John R. Falck, Ph.D., D.I.C. is a pioneer in arachidonic acid metabolism who has expedited the understanding of fatty acid metabolites generated by cytochrome P450 enzymes. As the Robert A. Welch Distinguished Chair in Chemistry and as a Professor of Biochemistry and Pharmacology at the University of Southwestern Medical Center in Dallas, Texas, Dr. Falck has extensively researched the application of synthetic and bioorganic chemistry to problems of biochemical and medicinal relevance. Dr. Falck has published over three hundred and fifty peer reviewed publications and holds several patents.

David Feldman, M.D. is the first clinician to explore the use of cytochrome P450 inhibitors to treat human disease, specifically for endocrinology and oncology indications. A prominent scientist in the vitamin D field with over two hundred peer reviewed publications; Dr. Feldman is a Professor of Medicine, Division of Endocrinology at the Stanford University School of Medicine, Stanford, California. Dr. Feldman has served as Chief of The Endocrinology Division at Stanford University School of Medicine for 10 years, and has served on editorial boards of *Endocrinology*, *Journal of Clinical Endocrinology and Metabolism* and publications committee *Journal of Bone and Mineral Research*.

Reuben Lotan, Ph.D. is a translational researcher who has bridged the basic science of retinoic acid pathways with the clinical use of retinoids. Dr. Lotan has published over three hundred and fifty peer reviewed articles, reviews and book chapters and serves on the editorial boards of leading cancer journals including the Journal of The National Cancer Institute and Cancer Research. Dr. Lotan is a Professor at The University of Texas, Department of Thoracic/Head and Neck Medical Oncology, and the Irving and Nadine Mansfield and Robert David Levitt Cancer Research Chair at the University of Texas, M.D. Anderson Cancer Center in Houston, Texas.

Michael R. Waterman, Ph.D. is the new Chair of Cytochroma's Scientific Advisory Board. As a Professor and Natalie Overall Warren Chair in Biochemistry, Vanderbilt University, School of Medicine Nashville, Tennessee, Dr. Waterman's research focuses on structure, function and induction of cytochrome P450s. Dr. Waterman has served on a number of editorial boards (DNA and Cell Biology, The Journal of Biological Chemistry, Molecular Endocrinology) including his current tenure with Archives of Biochemistry and Biophysics. Dr. Waterman also consults for a number of clients in industry, including Schering Plough and Cumberland Emerging Technologies.

Cytochroma Inc. is an applied genomics and drug discovery company. It is a world leader in the discovery of cytochrome P450 genes, the identification of the function of the proteins encoded by those genes, and the discovery of highly potent and specific drugs regulating cytochrome P450 enzymes to address unmet medical needs. To date, Cytochroma's drug discovery program has identified modulators of retinoic acid and calcitriol metabolism as drug candidates for the treatment of cancer, skin and inflammatory diseases. Cytochroma's Web site address is www.cytochroma.com.

